Cambridge Cognition really exciting position and pipeline of opportunities (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss its interim results. Matthew takes us through the highlights, having seen major contract wins across all product families and at all stages of clinical development expands on the company offering, how the company has been impacted by Covid-19 and describes the outlook for COG.

Cambridge Cognition Holdings and its subsidiaries develops and markets digital solutions to assess brain health for sale worldwide, principally in the UK, the US and Europe.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition AGM to be held on 27 May 2021

Cambridge Cognition Holdings plc (LON:COG) which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the Annual General Meeting

Cambridge Cognition Holdings

Cambridge Cognition – An excellent year for the company (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk to discuss preliminary results for 2020. Matthew talks us through the highlights, explains how the company performed during the pandemic, where sales orders across the portfolio came from, progress

Cambridge Cognition Holdings

Cambridge Cognition Strong financial performance revenues up 34%

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update and notice of results for the year ended 31 December 2020, together with details of a forthcoming change to